Vaxcyte, Inc. SEC filings PCVX

Vaxcyte, Inc. has 767 filings in SEC EDGAR's recent list, going back to Jul 24, 2015. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Vaxcyte, Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 23, 2026 —
DEF 14A Proxy statement Apr 23, 2026 Jun 15, 2026
DEFA14A Additional proxy material Apr 28, 2025 —
DEF 14A Proxy statement Apr 28, 2025 Jun 12, 2025
PRE 14A Preliminary proxy statement Apr 18, 2025 Jun 12, 2025
DEFA14A Additional proxy material Apr 15, 2024 —
DEF 14A Proxy statement Apr 15, 2024 Jun 6, 2024
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 —
DEFA14A Additional proxy material Apr 20, 2022 —
DEF 14A Proxy statement Apr 20, 2022 Jun 1, 2022
DEFA14A Additional proxy material Apr 14, 2021 —
DEF 14A Proxy statement Apr 14, 2021 Jun 2, 2021

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
PCVX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Carlos, CA
SEC filer status
Large accelerated filer
SEC CIK
1649094
Former names
SutroVax, Inc. (until Apr 3, 2020)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.